Malaria Pipeline Summary

DelveInsight’s, “Malaria - Pipeline Insight, 2026” report provides comprehensive insights about 44+ companies and 45+ pipeline drugs in Malaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malaria: Understanding

Malaria: Overview

Malaria is a potentially life-threatening parasitic disease caused by Plasmodium species and transmitted primarily through the bite of infected female Anopheles mosquitoes. Five species known to infect humans are P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi , with P. falciparum associated with the highest morbidity and mortality. The disease is characterized by fever and may progress to severe complications such as cerebral malaria, severe anemia, renal dysfunction, coma, and death if not promptly treated.

Malaria is caused by infection with Plasmodium parasites, which are transmitted to humans when an infected female Anopheles mosquito takes a blood meal. The major human-infecting species differ geographically: P. falciparum is predominant in sub-Saharan Africa and is associated with severe disease, while P. vivax is prevalent across South Asia, the Western Pacific, and Central America; P. ovale and P. malariae occur mainly in sub-Saharan Africa, and P. knowlesi is found primarily in Southeast Asia.

Following a mosquito bite, sporozoites enter the bloodstream and reach the liver, where they invade hepatocytes and develop into merozoites. These merozoites subsequently enter the bloodstream and invade red blood cells, progressing through ring, trophozoite, and schizont stages. Parasite replication ultimately causes erythrocyte rupture, releasing additional merozoites and inflammatory mediators. Infected erythrocytes can also adhere to vascular endothelium and become sequestered in small blood vessels, particularly in P. falciparum infection, contributing to severe manifestations such as cerebral malaria. In P. vivax and P. ovale infections, dormant liver-stage hypnozoites may persist and reactivate months or years later, resulting in relapse.

Diagnosis is primarily based on microscopic examination of Giemsa-stained thick and thin blood smears, which remains the gold-standard diagnostic method and allows detection, quantification of parasitemia, and identification of the infecting Plasmodium species. Rapid diagnostic tests (RDTs) detecting parasite antigens such as histidine-rich protein-2, lactate dehydrogenase, and aldolase can provide rapid diagnosis, while PCR is useful for detecting low-level parasitemia and confirming species. A single negative blood smear does not completely exclude malaria when clinical suspicion remains high, and repeat testing may therefore be required.

Treatment depends on the infecting Plasmodium species, disease severity, geographic region and associated drug resistance, and patient characteristics. Antimalarial therapy includes agents such as chloroquine or hydroxychloroquine, primaquine, artemisinin-based combination therapies (ACTs), and atovaquone-proguanil. ACTs are commonly used for P. falciparum infections, particularly in areas with chloroquine resistance, while primaquine is used against the dormant liver-stage hypnozoites of P. vivax and P. ovale to prevent relapse. Severe malaria requires urgent parenteral therapy, with intravenous artesunate being a key treatment option, together with supportive care and management of complications.

"Malaria- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malaria pipeline landscape is provided which includes the disease overview and Malaria treatment guidelines. The assessment part of the report embraces, in depth Malaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Malaria R&D. The therapies under development are focused on novel approaches to treat/improve Malaria.

Malaria Emerging Drugs Chapters

This segment of the Malaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malaria Emerging Drugs

• GSK3772701: GSK

GSK3772701, also known as MMV367/GSK701, is an investigational pyrrolidinamide antimalarial being developed for the treatment of Plasmodium falciparum malaria. It is a novel small-molecule candidate identified through phenotypic screening and demonstrates rapid activity against the parasite’s asexual blood stages. Its mechanism of action involves interfering with P. falciparum acyl-CoA synthetases 10 and 11 (ACS10/11), enzymes involved in parasite metabolic processes; ACS10 has been shown to be essential for asexual blood-stage parasite survival. By disrupting this pathway, GSK3772701 rapidly kills blood-stage parasites and represents a potential new mechanism distinct from currently used antimalarial therapies. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Malaria.

• INE963: Novartis AG

INE963 is an investigational antimalarial candidate developed by Novartis in collaboration with Medicines for Malaria Venture (MMV) for the treatment of uncomplicated malaria. It is a 5-aryl-2-amino-imidazothiadiazole (ITD) derivative designed to rapidly eliminate Plasmodium falciparum parasites during the asexual blood stage, including drug-resistant strains. INE963 has a novel mechanism of action, with studies demonstrating potent and rapid parasite-killing activity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Malaria.

• PfSPZ-LARC2: Sanaria Inc.

PfSPZ-LARC2 Vaccine is an investigational genetically attenuated whole-sporozoite vaccine being developed for the prevention of Plasmodium falciparum malaria. The vaccine contains P. falciparum sporozoites genetically modified through deletion of the Mei2 and LINUP genes, enabling the parasites to enter and develop within liver cells but preventing their progression beyond the late liver stage. Following administration, the attenuated parasites undergo controlled development in the liver and subsequently arrest before producing merozoites, thereby preventing establishment of blood-stage infection. This prolonged liver-stage exposure is designed to present a broad range of parasite antigens to the immune system and induce protective immune responses against subsequent P. falciparum infection. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Malaria.

• E1018: Eisai Inc.

E1018 is an investigational oral small-molecule antimalarial being developed by Eisai in collaboration with the Broad Institute for Plasmodium falciparum malaria. It is a protein synthesis inhibitor that targets the parasite’s phenylalanyl-tRNA synthetase (PfcPheRS), an enzyme required for protein synthesis. By inhibiting PfcPheRS, E1018 disrupts protein production in the malaria parasite, leading to parasite death and potentially providing activity against multiple parasite stages, with the aim of rapidly curing malaria and reducing recurrence and transmission. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Malaria.

Further product details are provided in the report……..

Malaria: Therapeutic Assessment

This segment of the report provides insights about the different Malaria drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Malaria

There are approx. 44+ key companies which are developing the therapies Malaria. The companies which have their Malaria drug candidates in the most advanced stage, i.e. Phase II include, GSK and others.

• Phases

DelveInsight’s report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Malaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malaria drugs.

Malaria Report Insights

• Malaria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malaria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malaria drugs?
• How many Malaria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malaria?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malaria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malaria and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GSK
• Novartis AG
• Eisai Inc.
• Vac4All
• Sail Biomedicines
• Sanaria
• Merck Sharp & Dohme LLC

Key Products

• GSK3772701
• GSK4024484
• E1018
• INE963
• LSA5-Biofusion
• MSP3-Biofusion
• LSA3-Biofusion
• eRNA-based malaria vaccine
• PfSPZ Vaccine
• MK-3868